
    
      This is a two part, Phase 1, open label, cross over study designed to evaluate the PK profile
      of crystalline PX-866 tablets relative to that of amorphous PX-866 capsules and to evaluate
      the effect of administration with food on the PK of crystalline PX-866 tablets in healthy
      volunteers.
    
  